Chromadex Reports Strong Q3 2024 with 31% Sales Increase
Company Announcements

Chromadex Reports Strong Q3 2024 with 31% Sales Increase

Chromadex ( (CDXC) ) has provided an update.

ChromaDex Corporation reported a strong third quarter in 2024, with a remarkable 31% increase in net sales, reaching $25.6 million. The growth was fueled by increased sales of Niagen® ingredients, including a significant rise in pharmaceutical-grade Niagen, resulting in a record net income of $1.9 million and an adjusted EBITDA of $2.9 million. The company expanded its Niagen+ product line to over 100 wellness clinics and continues to foster scientific research and development, positioning itself for future growth and innovation.

Learn more about CDXC stock on TipRanks’ Stock Analysis page.

Related Articles
TheFlyChromaDex reports Q3 EPS 2c, consensus 0c
TheFlyChromaDex sees FY24 revenue growth 15%
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App